Medicare Enrolled
Dr. Selwyn Levine, MD
Pulmonary Disease · Englewood, NJ
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Levine from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Levine?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Levine
Dr. Selwyn Levine is a pulmonary disease specialist in Englewood, NJ, with 20 years of NPI registration. Based on federal Medicare data, Dr. Levine performed 3,600 Medicare services across 2,520 unique beneficiaries.
Between the years covered by Open Payments, Dr. Levine received a total of $4,399 from 41 pharmaceutical and/or device companies across 299 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Levine is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 10% volume in NJ
$4,399 industry payments
Medicare Practice Summary
Medicare Utilization ↗3,600
Medicare services
Top 10% in NJ for pulmonary disease
2,520
Unique beneficiaries
$58
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~180 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
598 | $104 | $425 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
417 | $8 | $15 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
359 | $67 | $230 |
| Chest X-ray, 2 views An X-ray imaging test of the chest that captures two different angles to visualize the lungs, heart, and chest wall. |
284 | $8 | $36 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
195 | $0 | $5 |
| Electrocardiogram (EKG), 12-lead A standard heart rhythm test using at least 12 leads to record electrical activity. A healthcare provider interprets the results and provides a written report. |
181 | $10 | $50 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
169 | $17 | $70 |
| Pneumonia vaccine administration This procedure involves the injection of a vaccine to protect against pneumococcal disease. It is administered by a healthcare provider. |
155 | $34 | $90 |
| Pneumococcal conjugate vaccine (PCV20) An intramuscular injection of the 20-valent pneumococcal conjugate vaccine. It is used to protect against diseases caused by Streptococcus pneumoniae bacteria. |
138 | $283 | $800 |
| Annual wellness visit, follow-up A follow-up annual wellness visit that includes a personalized prevention plan of service. |
132 | $142 | $435 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
113 | $22 | $92 |
| Lung volume test using gas dilution or washout A test that measures the amount of air in your lungs by using a gas dilution or washout method. |
111 | $20 | $80 |
| Urinalysis, manual A manual laboratory examination of a urine sample to check for various substances and cells. |
105 | $3 | $15 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
104 | $34 | $73 |
| Flu vaccine, quadrivalent A flu shot containing four strains of the influenza virus to help prevent seasonal influenza infection. |
102 | $76 | $84 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
63 | $102 | $325 |
| Inhalation treatment for airway obstruction or sputum production A treatment involving the inhalation of medication to help clear airway obstructions or reduce sputum production. |
57 | $8 | $40 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
56 | $181 | $690 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
47 | $134 | $550 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
43 | $11 | $50 |
| Inhaled albuterol and ipratropium bromide via DME Administration of FDA-approved albuterol and ipratropium bromide medication through durable medical equipment. |
36 | $0 | $5 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
30 | $67 | $280 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
22 | $111 | $430 |
| Hospital discharge day management, 30 minutes or less This service covers the final day of hospital care when the patient is being discharged. It includes coordination of care and instructions for the patient within a time frame of 30 minutes or less. |
21 | $70 | $230 |
| Albuterol inhalation solution, 1 mg A unit dose of FDA-approved albuterol solution administered via durable medical equipment for inhalation. |
21 | $0 | $5 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
15 | $141 | $630 |
| Breathing device use evaluation An assessment of how a patient uses a breathing device. The provider reviews the patient's technique and device handling. |
14 | $16 | $65 |
| Pneumococcal vaccine, 23-valent A vaccine that protects against 23 types of pneumococcal bacteria. It is used to prevent infections caused by these bacteria. |
12 | $131 | $405 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$4,399
Total received (2018-2024)
Avg $628/year across 7 years
Top 35% in NJ for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
41
Companies
299
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,207 (95.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$193 (4.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$693
2023
$1,167
2022
$530
2021
$335
2020
$204
2019
$714
2018
$756
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$259
GlaxoSmithKline, LLC.
$134
Regeneron Healthcare Solutions, Inc.
$56
Mylan Specialty L.P.
$35
Boehringer Ingelheim Pharmaceuticals, Inc.
$34
United Therapeutics Corporation
$33
Vifor Pharma, Inc.
$30
Grifols USA, LLC
$20
Philips North America LLC
$20
Electromed, Inc.
$17
Merck Sharp & Dohme LLC
$14
ABBVIE INC.
$14
Azurity Pharmaceuticals, Inc.
$13
GENZYME CORPORATION
$13
Top 3 companies account for 64.8% of 2024 payments
All-time payments by company (2018-2024) ›
GlaxoSmithKline, LLC.
$1,299
AstraZeneca Pharmaceuticals LP
$504
Philips Electronics North America Corporation
$386
Mylan Specialty L.P.
$242
Boehringer Ingelheim Pharmaceuticals, Inc.
$241
Regeneron Healthcare Solutions, Inc.
$177
SANOFI-AVENTIS U.S. LLC
$177
Genentech USA, Inc.
$158
Sunovion Pharmaceuticals Inc.
$140
Electromed, Inc.
$137
Grifols USA, LLC
$88
Teva Pharmaceuticals USA, Inc.
$78
Insmed, Inc.
$77
GENZYME CORPORATION
$73
Merck Sharp & Dohme LLC
$70
United Therapeutics Corporation
$48
Amgen Inc.
$42
Circassia Pharmaceuticals Inc
$37
ARBOR PHARMACEUTICALS, INC.
$34
Actelion Pharmaceuticals US, Inc.
$31
Vifor Pharma, Inc.
$30
Harmony Biosciences LLC
$29
Baxter Healthcare
$29
Eisai Inc.
$26
Philips North America LLC
$20
IDORSIA PHARMACEUTICALS US INC
$17
Alexion Pharmaceuticals, Inc.
$16
CSL Behring
$16
Shire North American Group Inc
$15
Inogen, Inc.
$15
Covis Pharma GmBH
$15
Advanced Respiratory, Inc
$15
Janssen Pharmaceuticals, Inc
$15
HARMONY BIOSCIENCES LLC
$14
ABBVIE INC.
$14
JAZZ PHARMACEUTICALS INC.
$14
PFIZER INC.
$14
Azurity Pharmaceuticals, Inc.
$13
AngioDynamics, Inc.
$13
Merck Sharp & Dohme Corporation
$12
Nabriva Therapeutics, plc
$11
Top 3 companies account for 49.8% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · (AK6) Vest Therapy · AIRSUPRA · ALVESCO · ANORO · ANORO ELLIPTA · AREXVY · AVYCAZ · Arikayce · BELSOMRA · BREO · BREZTRI · BROVANA · Belviq · BioSentry Tract Sealant System · CAPVAXIVE · CINQAIR · DUPIXENT · DUPIXENT DUPILUMAB INJECTION · Dymista · Esbriet · FASENRA · GLASSIA · HORIZANT · Hillrom - Life 2000 Ventilation System · Horizant · INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH · LONHALA MAGNAIR · NIOX VERO · NUCALA · OFEV · OPSUMIT · OPSUMIT MACITENTAN · PNEUMOVAX 23 · PREVNAR 20 · Prolastin-C Liquid · QUVIVIQ · QVAR · Repatha · Respiratoriy Care Undiv · SMARTVEST · SPIRIVA · STEGLATRO · STIOLTO RESPIMAT · SYMBICORT · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · The Vest System Model 105 Home Care · Trilogy 100 · ULTOMIRIS · UTIBRON · Utibron · WAKIX · Wakix · Wellcentive Undiv · XARELTO · XYWAV · Xembify · Xenleta · Xolair · YUPELRI · Yupelri · Zemaira · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Pulmonary diseases within 10 mi
649
Per 100K population
68.0
County median income
$123,715
Nearest hospital
ENGLEWOOD HOSPITAL AND MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Levine is a clinical cardiology specialist, with above-average Medicare volume (top 10% in NJ), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Levine experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Levine performed 598 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Levine receive payments from pharmaceutical companies?
Yes. Dr. Levine received a total of $4,399 from 41 companies across 299 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Levine's costs compare to other pulmonary diseases in Englewood?
Dr. Levine's average Medicare payment per service is $58. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Levine) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Englewood
Browse pulmonary diseases in Englewood ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in NJ
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in NJ
Which NJ pulmonary diseases receive the most from drug and device companies.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Philips Electronics North America Corporation Payments to Doctors
See all physicians who received payments from Philips Electronics North America Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology